Search

Displaying results 6061 - 6070 of 10000 in total
  1. Drug

    Pexelizumab

    go.drugbank.com/drugs/DB04949
    Investigational

    Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.

  2. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

    Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-Ring
  3. Drug

    Oregovomab

    go.drugbank.com/drugs/DB04964
    Investigational

    Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

  4. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    It is a member of a new family of pharmaceutical compounds called vomeropherins.

  5. Drug

    Reglitazar

    go.drugbank.com/drugs/DB04971
    Experimental

    Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation

  7. Drug

    Imisopasem manganese

    go.drugbank.com/drugs/DB04976
    Investigational

    M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.

  8. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. … SP1049C is a novel anthracycline chemotherapeutic agent containing [doxorubicin] and two nonionic pluronic block copolymers.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: doxorubicin with pluronics F-127 and L-61, Doxorubicin HCl with pluronic L-61 and pluronic F-127
  9. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  10. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.